Literature DB >> 21048907

Endocrine Treatment - 'Old-Fashioned' Therapy Becoming Redundant in an Era of Molecular Medicine?

Per Eystein Lønning1.   

Abstract

Year:  2008        PMID: 21048907      PMCID: PMC2931024          DOI: 10.1159/000174341

Source DB:  PubMed          Journal:  Breast Care (Basel)        ISSN: 1661-3791            Impact factor:   2.860


× No keyword cloud information.
  24 in total

1.  Endocrine therapy and bone loss in breast cancer: time to close in the RANK(L)?

Authors:  Per E Lønning
Journal:  J Clin Oncol       Date:  2008-08-25       Impact factor: 44.544

2.  Goserelin versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy in premenopausal patients with node-positive breast cancer: The Zoladex Early Breast Cancer Research Association Study.

Authors:  W Jonat; M Kaufmann; W Sauerbrei; R Blamey; J Cuzick; M Namer; I Fogelman; J C de Haes; A de Matteis; A Stewart; W Eiermann; I Szakolczai; M Palmer; M Schumacher; M Geberth; B Lisboa
Journal:  J Clin Oncol       Date:  2002-12-15       Impact factor: 44.544

3.  Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group.

Authors: 
Journal:  Lancet       Date:  1998-05-16       Impact factor: 79.321

4.  Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial.

Authors:  Raimund Jakesz; Walter Jonat; Michael Gnant; Martina Mittlboeck; Richard Greil; Christoph Tausch; Joern Hilfrich; Werner Kwasny; Christian Menzel; Hellmut Samonigg; Michael Seifert; Guenther Gademann; Manfred Kaufmann; Johann Wolfgang
Journal:  Lancet       Date:  2005 Aug 6-12       Impact factor: 79.321

5.  Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: a meta-analysis of four randomized trials.

Authors:  J G Klijn; R W Blamey; F Boccardo; T Tominaga; L Duchateau; R Sylvester
Journal:  J Clin Oncol       Date:  2001-01-15       Impact factor: 44.544

6.  High-dose estrogen treatment in postmenopausal breast cancer patients heavily exposed to endocrine therapy.

Authors:  P E Lønning; P D Taylor; G Anker; J Iddon; L Wie; L M Jørgensen; O Mella; A Howell
Journal:  Breast Cancer Res Treat       Date:  2001-05       Impact factor: 4.872

7.  Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer.

Authors:  Edward H Romond; Edith A Perez; John Bryant; Vera J Suman; Charles E Geyer; Nancy E Davidson; Elizabeth Tan-Chiu; Silvana Martino; Soonmyung Paik; Peter A Kaufman; Sandra M Swain; Thomas M Pisansky; Louis Fehrenbacher; Leila A Kutteh; Victor G Vogel; Daniel W Visscher; Greg Yothers; Robert B Jenkins; Ann M Brown; Shaker R Dakhil; Eleftherios P Mamounas; Wilma L Lingle; Pamela M Klein; James N Ingle; Norman Wolmark
Journal:  N Engl J Med       Date:  2005-10-20       Impact factor: 91.245

8.  Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial.

Authors:  M Baum; A U Budzar; J Cuzick; J Forbes; J H Houghton; J G M Klijn; T Sahmoud
Journal:  Lancet       Date:  2002-06-22       Impact factor: 79.321

9.  Randomized clinical trial of diethylstilbestrol versus tamoxifen in postmenopausal women with advanced breast cancer.

Authors:  J N Ingle; D L Ahmann; S J Green; J H Edmonson; H F Bisel; L K Kvols; W C Nichols; E T Creagan; R G Hahn; J Rubin; S Frytak
Journal:  N Engl J Med       Date:  1981-01-01       Impact factor: 91.245

10.  Strength and weakness of phase I to IV trials, with an emphasis on translational aspects.

Authors:  Per Eystein Lønning
Journal:  Breast Cancer Res       Date:  2008-12-18       Impact factor: 6.466

View more
  1 in total

1.  Sex Steroid Hormones Regulate Leptin Transcript Accumulation and Protein Secretion in 3T3-L1 Cells.

Authors:  Mónica Z Jenks; Heather E Fairfield; Erik C Johnson; Ron F Morrison; Gloria K Muday
Journal:  Sci Rep       Date:  2017-08-15       Impact factor: 4.379

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.